Compare compounds
Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.
Peptijournal · Retatrutide · https://peptijournal.com/compare?c=retatrutide · Printed
Retatrutide
Same goal
01Protocol
- Start
- 2 mg
- Range
- 2–12 mg
- Frequency
- Once weekly
- Cycle
- Ongoing, titrated every 4 weeks
- Vials
- 10 / 20 / 30 mg
- Titration
- Weeks 1–4: 2 mg
- Weeks 5–8: 4 mg
- Weeks 9–12: 8 mg
- Weeks 13+: 12 mg (highest trial arm)
02Quick calculator
03Mechanism of action
Retatrutide (LY3437943) is a single peptide agonist of three receptors: GIP, GLP-1 and glucagon. Adding glucagon-receptor activity is studied for increasing energy expenditure and liver-fat effects on top of the appetite effects of GIP/GLP-1 agonism.
04Study endpoints
- Phase 2 obesity trial (338 adults): mean weight change at 48 weeks ranged from −8.7% to −24.2% across arms vs −2.1% with placebo.
- In the highest arm, 83% of participants lost 15% or more of body weight at 48 weeks, vs 2% on placebo.
- Preclinical and early clinical work describes glycaemic and weight effects from combined triple-receptor agonism.
05Safety & regulatory findings
- Investigational: not approved by the FDA or EMA for any indication. Phase 3 trials are ongoing.
- Phase 2 adverse events were mainly gastrointestinal and dose-related; heart-rate increases were also reported.
06Citations
2 references · view